The FDA approved Eylea HD for the treatment of macular edema following retinal vein occlusion, according to a press release.
Eylea HD (aflibercept 8 mg, Regeneron) is now indicated for treating retinal vein occlusion (RVO) with dosing intervals of up to every 8 weeks after an initial monthly dosing period.
This recent approval also allows for monthly dosing for RVO as well as the previously approved indications of wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy “for some patients who may benefit from resuming this dosing schedule,” according to the press